Stockreport

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Vaxcyte, Inc.  (PCVX) 
PDF -- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adul [Read more]